BioLink is a specialty pharmaceutical company focused on the development and commercialization of patented treatments to meet the needs of underserved patient populations. 

​

BioLink builds on reformulations of “gold standards of care” to provide novel treatments eligible for approval using 505(b)(2) New Drug Applications.

​

BioLink Specifics

• Focus on enhancement of standard of care treatments for chronic diseases

• Pipeline depth & breadth: 5 drugs; multiple indications

• Speed to market: 1 – 5 years

• Minimal clinical risk: Established safety & efficacy

• Limited development cost: < $10 million per drug for 505(b)(2) candidates

• Experienced drug development team

​

BioLink Management Team

• Dr. Deanna Nelson, President

• Mr. Keith Satisky, General Counsel

​

BioLink Advisory Team

• Ms. Nancy Chew, Regulatory Affairs North America

• Dr. J. Mitchell Jones, Casimir Jones, Patent Attorneys

• Mr. George Conbeer, Business Affairs (L,M&A)

• Mr. John Spitznagel, Jr., Pharmaceutical Affairs

​

BioLink’s Research Collaborators

• Dr. Chad Stahl, North Carolina State University

• Dr. Jack Odle, North Carolina State University

• Dr. Keith Hruska, Washington University, St. Louis

• Dr. Dennis Miller, Cornell University

• Dr. David Driscoll, UMass Medical School

​

​